Cargando…
Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatinib has been shown to be more effective in in vitro st...
Autores principales: | Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Nagasawa, Ryo, Tanaka, Katsushi, Kubo, Sousuke, Katakura, Seigo, Chen, Hao, Hirama, Nobuyuki, Ushio, Ryota, Aoki, Ayako, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Hiroki, Horita, Nobuyuki, Watanabe, Keisuke, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396380/ https://www.ncbi.nlm.nih.gov/pubmed/32495514 http://dx.doi.org/10.1111/1759-7714.13503 |
Ejemplares similares
-
MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
por: Katakura, Seigo, et al.
Publicado: (2020) -
T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021) -
Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
por: Teranishi, Shuhei, et al.
Publicado: (2020) -
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021) -
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)